NCT06973824 A Twenty-years' Experience in Pituitary Disease.
| NCT ID | NCT06973824 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Pituitary Adenoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,600 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2028-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,600 participants in total. It began in 2025-03-10 with a primary completion date of 2028-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.
Eligibility Criteria
Inclusion Criteria: * Patients underwent surgery for pituitary tumors; * pathology diagnosis of pituitary tumors; * patients older then 18 years at diagnosis of pituitary tumors; * 2 years follow-up; Exclusion Criteria: * age lower then 18 years * follow-up shorter than 2 years
Contact & Investigator
Francesco Doglietto, Prof
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06973824 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pituitary Adenoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06973824 currently recruiting?
Yes, NCT06973824 is actively recruiting participants. Contact the research team at francesco.doglietto@policlinicogemelli.it for enrollment information.
Where is the NCT06973824 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06973824 clinical trial?
NCT06973824 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Francesco Doglietto, Prof at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 1,600 participants.